Immunotherapy

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

By

In an analysis of 11 studies, researchers investigated whether the benefits of carfilzomib for multiple myeloma outweigh the cardiovascular risks. However, the researchers recommend careful monitoring and management of blood pressure and volume status as good clinical practice, regardless.

Drug Classification of Trastuzumab

Drug Classification of Trastuzumab

By

Is trastuzumab classified as an immunotherapy? If so, how does it work?

Navigating the Benefits and Challenges of Immunotherapy

Navigating the Benefits and Challenges of Immunotherapy

By

A review of immunotherapy — what they are, how they work, and what to watch for — was presented at the 2018 ONA Navigation Summit.

Are Ovarian Cancer Stem Cells the Target for Innovative Immunotherapy?

Are Ovarian Cancer Stem Cells the Target for Innovative Immunotherapy?

[OncoTargets and Therapy] In a review of cancer stem cells (CSCs)/ovarian cancer stem cells (OCSCs), researchers discuss the implications of immunotherapy development based on studying cancer evolution by CSCs, and targeting OCSC surface markers to develop CAR-T immunotherapy.

Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers

Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers

By

Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.

Durable Response Achieved With Nivolumab in Untreated Melanoma Brain Metastases

Durable Response Achieved With Nivolumab in Untreated Melanoma Brain Metastases

By

In this phase 2 study, researchers randomly assigned 79 patients with immunotherapy-naive melanoma with brain metastases to receive either nivolumab plus ipilimumab or nivolumab alone.

Dabrafenib-Trametinib Combination Approved for Mutation-Positive Thyroid Cancer

Dabrafenib-Trametinib Combination Approved for Mutation-Positive Thyroid Cancer

By

FDA grants approval to immunotherapy combination in the treatment of unresectable and metastatic BRAF V600E mutation-positive anaplastic thyroid cancer (ATC).

Preexisting Rheumatoid Disease Not a Deterrent to Immune Checkpoint Inhibitor Therapy

Preexisting Rheumatoid Disease Not a Deterrent to Immune Checkpoint Inhibitor Therapy

By

Investigators reviewed clinical data from patients with cancer and pre-existing rheumatic disease treated with ipilimumab, nivolumab, or pembrolizumab.

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

By

A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.

Intratumor Rotavirus Therapy Has Potential to Overcome Immunotherapy Resistance

Intratumor Rotavirus Therapy Has Potential to Overcome Immunotherapy Resistance

In immunocompetent murine models of lymphoma and neuroblastoma, IT rotavirus therapy demonstrated that it can overcome immune checkpoint inhibitor resistance.

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

By

In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.

Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma

Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma

By

Researchers report on finding of a double-blind phase 3 study on the efficacy of adjuvant vemurafenib in patients with resected stage IIC to IIIB melanoma.

Axitinib Plus Pembrolizumab Shows Promise in Treatment-Naïve Advanced RCC

Axitinib Plus Pembrolizumab Shows Promise in Treatment-Naïve Advanced RCC

By

Nonrandomized trial demonstrates tolerability and antitumor activity of a PD-1 checkpoint inhibitor plus a VEGF-TKI in patients with treatment-naïve advanced RCC.

Immunotherapy Tolerable for Cancer Patients With Rheumatologic Disease

Immunotherapy Tolerable for Cancer Patients With Rheumatologic Disease

By

In this retrospective study, researchers sought to determine if cancer patients with rheumatologic disease would be able to tolerate cancer treatment with immune checkpoint inhibitors or if these agents would induce a rheumatologic disease flare.

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

By

Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

By

Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

By

Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).

FDA Grants Breakthrough Therapy Designation to Ribociclib for HR+/HER2- Breast Cancer

FDA Grants Breakthrough Therapy Designation to Ribociclib for HR+/HER2- Breast Cancer

By

FDA grants Breakthrough Therapy designation for ribociclib as an initial endocrine-based therapy for HR+/HER2- breast cancer in premenopausal or perimenopausal women.

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

By

Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

By

The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.

Epigenetic Modulation, Checkpoint Inhibition Showed Potential in HER2 Breast Cancer

Epigenetic Modulation, Checkpoint Inhibition Showed Potential in HER2 Breast Cancer

By

Using a mouse model of HER2+ breast cancer, researchers tested the efficiency of combined epigenetic modulation and checkpoint inhibition using the histone deacetylase inhibitor ENT and antibodies for 2 checkpoint inhibitor proteins. These findings were presented at the 2017 SABCS.

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

By

Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.

Examining the Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer

Examining the Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer

By

Breast cancer was previously thought to not be immunogenic in nature, but a subset of patients with breast cancer, primarily with triple negative disease, have exhibited robust levels of tumor infiltrating leukocytes.

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

By

US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.

Granulocyte Colony-Stimulating Factors: Use, Administration, Adverse Effects

Granulocyte Colony-Stimulating Factors: Use, Administration, Adverse Effects

By

A review of granulocyte colony-stimulating factors, dosage and administration, adverse effects, and nurse management steps is presented.

Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia

Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia

By

A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

By

Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

By

Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatments.

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

By

Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.

Cannabis Reduces Response Rate to Immunotherapy for Cancer

Cannabis Reduces Response Rate to Immunotherapy for Cancer

By

Investigators report that administering cannabis to patients with cancer undergoing immunotherapy was found to lower the response rate to therapy but had no effect on PFS or OS, in an oral presentation at ESMO 2017 Congress.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs